Status:
UNKNOWN
Interest of a Therapeutic Follow-up of the Cytarabine in the Acute Myeloid Leukaemia: Is There Constitutional Biomarkers
Lead Sponsor:
Assistance Publique Hopitaux De Marseille
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
In this open-label, single-center, non-randomized patients with AML (Acute Myeloid Leukemia) and receiving all induction chemotherapy and consolidation consisting of cytarabine under the care usual fo...
Detailed Description
Background and Rationale: The development of personalized medicine in oncology has so far relied on the use of somatic biomarkers to inform the therapist about the choice of the molecule or molecules ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patient aged over 18 years old
- Patient with acute myeloid leukemia
- Patient treated with cytarabine
- Patient having signed an informed consent form
- Patient having signed an authorization to practice a constitutional genetic analysis
- Need for effective contraception in patients of childbearing age.
- Patient affiliated to a social security scheme
- Exclusion Criteria
- Not obtaining free, informed and signed consent
- Patient participating in another biomedical research
- Pregnant patients
Exclusion
Key Trial Info
Start Date :
June 21 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2018
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03337516
Start Date
June 21 2017
End Date
December 31 2018
Last Update
November 9 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assistance Publique - Hopitaux de Marseille
Marseille, France